<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-JSOC3X7M</identifier><date>2022</date><creator>Štrukelj, Borut</creator><relation>documents/doc/J/URN_NBN_SI_doc-JSOC3X7M_001.pdf</relation><relation>documents/doc/J/URN_NBN_SI_doc-JSOC3X7M_001.txt</relation><format format_type="issue">1</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 75-76</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">103051267</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-JSOC3X7M</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Farmacija</subject><title>evropska agencija za zdravila izdala kar za 92 pozitivnih mnenj za nova zravila</title><title>Leto 2021</title><title>novice iz sveta farmacije</title></Record>